This educational activity will review the efficacy, safety, and tolerability data for overactive bladder pharmacologic therapies, including current and emerging β3-adrenoceptor agonists.

This educational activity is based on the proceedings of a symposium held in conjunction with the 95th Annual Meeting of the North Central Section of the American Urological Association on OAB that reviewed updates in the treatment of OAB, including clinical data on new and emerging treatments, and which highlighted some of the evidence on the increased risk of dementia associated with antimuscarinic use.